Kyowa Hakko Kogyo Co., Ltd.

Taisho Pharmaceutical Co., Ltd.

Nisshin Flour Milling Co., Ltd.

Other

Jeol Ltd.

Astellas Pharma Gmbh

Meiji Seika Kaisha, Ltd.

Yamanouchi Pharmaceutical Company Ltd.

Nippon Chemiphar Co., Ltd.

Sosei Co., Ltd.

Kyowa Hakko Bio Co., Ltd.

Haruo Seto

Noboru Otake

Kazuo Shin-Ya

Shinichi Hashimoto

Akio Ozaki

Tomohisa Kuzuyama

Hiroaki Motoyama

Koichiro Miyake

Shunji Takahashi

Sadafumi Omura

Kazutoshi Mizoue

Michio Yamagishi

Taku Mizutani

Masanori Sugita

Tetsuo Sasaki

Akira Kawashima

Hiroshi Hara

Koji Nagai

Shigeru Hiramoto

Nobuaki Shindo

Konstanty Wierzba

Masamichi Mori

Nakako Arao

Kazuma Kamigiri

Kazuo Furihata

Kinya Souda

Toshihiro Takahashi

Toru Sasaki

Yutaka Nomura

Takashi Yaguchi

Akinori Suzuki

Noriyoshi Sueda

Akira Isogai

Muneki Ohuchi

Yohei Natori

Shogo Matsumoto

Shohei Sakuta

Mitsuo Ogura

Shinichi Lsp Machida 1203 Hashimoto

Shunji Greenhouse B 102 Takahashi

The present invention provides a process for producing isoprenoid compounds or proteins encoded by DNA using DNA that contains one or more of the DNA encoding proteins having activity to improve efficiency in the biosynthesis of isoprenoid compounds effective in pharmaceuticals for cardiac diseases, osteoporosis, homeostasis, prevention of cancer, and immunopotentiation, health food and anti-fouling paint products against barnacles; the DNA; the protein; and a method for screening a substance with antibiotic and weeding activities comprising screening a substance inhibiting enzymatic reaction on the non-mevalonate pathway.

Process for producing isoprenoid compounds by microorganisms and a method for screening compounds with antibiotic or weeding activity

A compound which has the following formula (1), a process for its production, a pharmaceutical composition comprising the compound as an active ingredient, a method of treating tumor which comprises administering the compound, use of the compound as a medicine, and a microorganism capable of producing the compound. The compound of the present invention is a novel compound which has antitumor action and is useful as a medicine.

[object Object]

This invention relates to a novel compound which has a cytotoxic activity and TGF-&#x3b2; like activity for human cancer cells and is useful as an antitumor agent and to a pharmaceutical composition which contains the same.

Depsipeptide compound

The present invention provides a process for producing isoprenoid compounds or proteins encoded by DNA using DNA that contains one or more of the DNA encoding proteins having activity to improve efficiency in the biosynthesis of isoprenoid compounds effective in pharmaceuticals for cardiac diseases, osteoporosis, homeostasis, prevention of cancer, and immunopotentiation, health food and anti-fouling paint products against barnacles the DNA; the protein; and a method for screening a substance with antibiotic and weeding activities comprising screening a substance inhibiting enzymatic reaction on the non-mevalonate pathway.

This invention relates to a novel compound which has a cytotoxic activity and TGF-&bgr; like activity for human cancer cells and is useful as an antitumor agent and to a pharmaceutical composition which contains the same.

Substance GM-95, process for producing the same and utilization thereof

A substance PF1191 having an inhibitory activity to kainic acid toxicity represented by the following formula (I) which is obtained by incubating a fungus belonging to the genus Eupenicillium and isolating the product thus produced from the culture by solvent extraction, adsorption column chromatography, gel filtration, etc.

Physiologically active substance PF1191 and process for producing the same

Dihydrophenazinecarboxylic acid derivatives

New compound, designated as leucanicidin, is now provided and is useful as insecticide. Leucanicidin is fermentatively produced by a microorganism Streptomyces halstedii No. 3002-14 (identifiable as FERM BP-493).

Leucanicidin

The present invention provides a nuclear magnetic resonance spectroscopy that permits one to see changes in spectra without the use of long-range coupling even if the obtained resonance lines split into complex multiplet patterns. The spectrometry comprises the steps of: (a) applying a pulse train of radio-frequency irradiation to a nucleus under observation; (b) applying weak radio-frequency irradiation having a frequency equal to the resonance frequency either of an unobserved nucleus coupled to the observed nucleus or of the observed nucleus in synchronism with the application of the pulse train; (c) receiving the free induction decay signal produced after the application of the pulse train and storing it in a memory; (d) applying a pulse train of radio-frequency irradiation to the observed nucleus; (e) receiving the free induction decay signal produced after the application of the pulse train in step (d) and either adding it to the free induction decay signal stored in step (c) or substracting it from the previously stored signal; and (f) taking the Fourier transform of the free induction decay signal obtained by the arithmetic operation in step (e).

Nuclear magnetic resonance spectroscopy

Mycotrienin-related compounds called the T-23-X, -XI, -XII, -XIII and -XIV. These compounds are isolated and characterized by structural formula and other identifying data. They are useful in the treatment of tumors.

Mycotrienin-related compounds

Mycotrienin-related compounds called the T-23-VIII and T-23-IX substances. These substances are isolated and characterized by structural formula and other identifying data. These substances are useful in the treatment of tumors.

Growing community of inventors

Tokyo, Japan

Haruo Seto